AR124123A1 - Anticuerpos anti-cd25 - Google Patents

Anticuerpos anti-cd25

Info

Publication number
AR124123A1
AR124123A1 ARP210103224A ARP210103224A AR124123A1 AR 124123 A1 AR124123 A1 AR 124123A1 AR P210103224 A ARP210103224 A AR P210103224A AR P210103224 A ARP210103224 A AR P210103224A AR 124123 A1 AR124123 A1 AR 124123A1
Authority
AR
Argentina
Prior art keywords
seq
cdr1
cdr2
cdr3
cdrs
Prior art date
Application number
ARP210103224A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Olive
Armand Bensussan
Jrme Giustiniani
Anne Marie-Cardine
Arnaud Foussat
Jemila Houacine
Original Assignee
Inst Nat Sante Rech Med
Inst Jean Paoli & Irene Calmettes
Alderaan Biotechnology
Centre Nat Rech Scient
Univ D’Aix Marseille
Univ Paris
Univ Paris Val De Marne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Inst Jean Paoli & Irene Calmettes, Alderaan Biotechnology, Centre Nat Rech Scient, Univ D’Aix Marseille, Univ Paris, Univ Paris Val De Marne filed Critical Inst Nat Sante Rech Med
Publication of AR124123A1 publication Critical patent/AR124123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP210103224A 2020-11-20 2021-11-19 Anticuerpos anti-cd25 AR124123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20306424 2020-11-20

Publications (1)

Publication Number Publication Date
AR124123A1 true AR124123A1 (es) 2023-02-15

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103224A AR124123A1 (es) 2020-11-20 2021-11-19 Anticuerpos anti-cd25

Country Status (9)

Country Link
US (1) US20240002522A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247497A1 (cg-RX-API-DMAC7.html)
JP (1) JP7886328B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118108A (cg-RX-API-DMAC7.html)
CN (1) CN116917318A (cg-RX-API-DMAC7.html)
AR (1) AR124123A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021380966A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022106665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019008386A1 (en) * 2017-07-06 2019-01-10 Tusk Therapeutics Ltd COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN114630838A (zh) * 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体

Also Published As

Publication number Publication date
JP2023550446A (ja) 2023-12-01
EP4247497A1 (en) 2023-09-27
CN116917318A (zh) 2023-10-20
US20240002522A1 (en) 2024-01-04
KR20230118108A (ko) 2023-08-10
AU2021380966A1 (en) 2023-06-22
CA3199006A1 (en) 2022-05-27
JP7886328B2 (ja) 2026-07-07
WO2022106665A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
PE20030846A1 (es) Anticuerpos para cd40
JP2019201643A5 (cg-RX-API-DMAC7.html)
JP2017052784A5 (cg-RX-API-DMAC7.html)
RU2013153527A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
IL299221A (en) Cd3 binding antibodies
AR109715A1 (es) Anticuerpos anti-cd27
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
PE20181051A1 (es) Anticuerpo anti-epha4
AR123306A1 (es) Anticuerpos fgfr3 y métodos de uso
FI3515947T3 (fi) Uudet tekijän XI vasta-aineet ja niiden käyttökohteet
CO6180454A2 (es) Anticuerpos de la egfl7 y metodos de uso
JP2022517216A5 (cg-RX-API-DMAC7.html)
PE20252392A1 (es) Anticuerpos biespecificos que se dirigen a pd1 y vegf
PE20250390A1 (es) Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
AR134791A1 (es) Composiciones farmacéuticas de anticuerpos que se unen a interleucina 13
PE20212269A1 (es) Anticuerpos anti-trem1 y metodos relacionados
IL277899B1 (en) Methods and compositions for treating yellow fever
AR129472A1 (es) Anticuerpos anti-bcma

Legal Events

Date Code Title Description
FB Suspension of granting procedure